慢性疲労症候群治療薬の世界市場

慢性疲労症候群治療薬の世界市場は2030年までに2億9,020万米ドルに達する見込み

2023年に2億3,990万米ドルと推定された慢性疲労症候群治療薬の世界市場は、2030年には2億9,020万米ドルに達し、分析期間2023-2030年のCAGRは2.8%で成長すると予測されます。本レポートで分析したセグメントの1つである鎮痛剤＆NSAIDsは、CAGR 4.1％を記録し、分析期間終了時には1億3,750万米ドルに達すると予測されます。抗うつ薬・抗精神病薬セグメントの成長率は、分析期間中CAGR 1.9％と推定されます。

米国市場は推定6,540万米ドル、中国はCAGR 5.7％で成長予測

米国の慢性疲労症候群治療薬市場は2023年に6,540万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 5.7%で成長し、2030年には市場規模が5,940万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.7%と2.1%と予測されています。欧州では、ドイツがCAGR 1.4%で成長すると予測されています。

世界の慢性疲労症候群治療薬市場- 主な促進要因と動向まとめ

筋痛性脳脊髄炎（ME）としても知られる慢性疲労症候群（CFS）は、休息しても改善せず、身体的・精神的活動によって悪化する極度の疲労を特徴とする複雑で衰弱性の疾患です。この疾患は、筋肉痛、認知障害、睡眠障害、頭痛などの様々な症状を伴うことが多いです。CFSの正確な原因は不明であるが、遺伝的、環境的、心理的要因が組み合わさって生じているものと考えられています。CFSの治療法は、現在、治療法がないため、症状を改善し、生活の質を向上させることに重点がおかれています。

CFSの治療法は、個人差が大きく、薬理学的、非薬理学的アプローチを組み合わせておこなうことができます。薬物療法には、鎮痛剤、抗うつ剤、睡眠導入剤など、特定の症状を抑えるための薬剤が含まれます。その他の特典として、特に基礎に感染症や免疫機能障害が認められる場合には、抗ウイルス薬や免疫調整療法が有効な患者もいます。非薬物療法は、CFS治療において重要な役割を果たしており、認知行動療法（CBT）、段階的運動療法（GET）、省エネルギーやストレス軽減を目的とした生活習慣の改善などが含まれる。また、症状を緩和し、全体的な健康状態を改善するために、栄養支援や鍼治療、瞑想などの補完療法も一般的におこなわれています。

慢性疲労症候群治療薬市場の成長は、いくつかの要因によってもたらされます。第一に、CFSの認知度や診断の増加は、認知度の向上や擁護活動もあり、効果的な治療に対する需要の高まりにつながっています。第二に、医学研究の進歩により、CFSの複雑な病態生理が徐々に解明されつつあり、新たな治療ターゲットや治療アプローチへの道が開かれつつあります。また、個別化医療への注目の高まりも、患者のプロファイルに合わせた治療が可能になることから、市場の成長に寄与しています。さらに、新興市場におけるヘルスケアインフラの拡充や専門的治療へのアクセスは、 CFS治療の有効性を高めています。製薬会社と研究機関の戦略的提携は、新たな治療法の開発を加速させています。さらに、デジタルヘルス技術の台頭により、患者の管理・サポートが強化され、症状の追跡や治療のアドヒアランスが向上しています。最後に、CFS研究への資金提供の増加や包括的な臨床ガイドラインの開発により、この困難な疾患に対するより体系的で効果的なアプローチが促進されています。

調査対象企業の例（全86件）

• AIM ImmunoTech Inc.
• Berlin Cures Holding AG
• HiFiBiO Therapeutics
• Mallinckrodt Pharmaceuticals
• Mitodicure GmbH
• Mitsubishi Tanabe Pharma Corporation
• Moleculera Biosciences
• Novartis International AG
• Otsuka Novel Products GmbH
• Pfizer, Inc.
• PrecisionLife Ltd.
• Teva Pharmaceutical Industries Ltd.
• Tonix Pharmaceuticals Holding Corporation
• Viatris, Inc.
• Virios Therapeutics

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Chronic Fatigue Syndrome Therapeutics Market to Reach US$290.2 Million by 2030

The global market for Chronic Fatigue Syndrome Therapeutics estimated at US$239.9 Million in the year 2023, is expected to reach US$290.2 Million by 2030, growing at a CAGR of 2.8% over the analysis period 2023-2030. Pain Relievers & NSAIDs, one of the segments analyzed in the report, is expected to record a 4.1% CAGR and reach US$137.5 Million by the end of the analysis period. Growth in the Antidepressant & Antipsychotic Drugs segment is estimated at 1.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$65.4 Million While China is Forecast to Grow at 5.7% CAGR

The Chronic Fatigue Syndrome Therapeutics market in the U.S. is estimated at US$65.4 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$59.4 Million by the year 2030 trailing a CAGR of 5.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.7% and 2.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Chronic Fatigue Syndrome Therapeutics Market - Key Drivers and Trends Summarized

Chronic Fatigue Syndrome (CFS), also known as Myalgic Encephalomyelitis (ME), is a complex and debilitating disorder characterized by extreme fatigue that does not improve with rest and is worsened by physical or mental activity. This condition often includes a range of symptoms such as muscle pain, cognitive difficulties, sleep disturbances, and headaches. The exact cause of CFS remains unknown, and it is believed to result from a combination of genetic, environmental, and psychological factors. Therapeutic approaches for CFS focus on managing symptoms and improving quality of life, as there is currently no cure for the condition.

Treatment strategies for CFS are highly individualized and may involve a combination of pharmacological and non-pharmacological approaches. Pharmacological treatments include medications to manage specific symptoms such as pain relievers, antidepressants, and sleep aids. Additionally, some patients benefit from antiviral medications or immune-modulating therapies, particularly if there is evidence of an underlying infection or immune dysfunction. Non-pharmacological treatments play a crucial role in CFS management and may include cognitive behavioral therapy (CBT), graded exercise therapy (GET), and lifestyle modifications aimed at energy conservation and stress reduction. Nutritional support and complementary therapies such as acupuncture and meditation are also commonly utilized to alleviate symptoms and enhance overall well-being.

The growth in the Chronic Fatigue Syndrome therapeutics market is driven by several factors. Firstly, increasing recognition and diagnosis of CFS, partly due to greater awareness and advocacy efforts, have led to a higher demand for effective treatments. Secondly, advancements in medical research are gradually unraveling the complex pathophysiology of CFS, paving the way for novel therapeutic targets and treatment approaches. The growing focus on personalized medicine is also contributing to market growth, as treatments can be tailored to individual patient profiles. Additionally, the expansion of healthcare infrastructure and access to specialized care in emerging markets is improving the availability of CFS treatments. Strategic collaborations between pharmaceutical companies and research institutions are accelerating the development of new therapies. Furthermore, the rise of digital health technologies is enhancing patient management and support, facilitating better symptom tracking and treatment adherence. Lastly, increased funding for CFS research and the development of comprehensive clinical guidelines are fostering a more structured and effective approach to managing this challenging condition.

Select Competitors (Total 86 Featured) -

• AIM ImmunoTech Inc.
• Berlin Cures Holding AG
• HiFiBiO Therapeutics
• Mallinckrodt Pharmaceuticals
• Mitodicure GmbH
• Mitsubishi Tanabe Pharma Corporation
• Moleculera Biosciences
• Novartis International AG
• Otsuka Novel Products GmbH
• Pfizer, Inc.
• PrecisionLife Ltd.
• Teva Pharmaceutical Industries Ltd.
• Tonix Pharmaceuticals Holding Corporation
• Viatris, Inc.
• Virios Therapeutics

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Global Economic Update
  • Chronic Fatigue Syndrome Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Awareness of Chronic Fatigue Syndrome (CFS) Drives Demand for Therapeutics
  • Advancements in Diagnostic Technologies Propel Growth in CFS Therapeutics Market
  • Growing Focus on Research and Development Expands Addressable Market Opportunity
  • Innovations in Symptom Management and Supportive Care Strengthen Business Case for Therapeutics
  • Increasing Focus on Holistic and Integrative Medicine Approaches Expands Market Opportunities
  • Enhanced Patient Outcomes Through Multidisciplinary Care Approaches Strengthen Market Demand
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Chronic Fatigue Syndrome Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Pain Relievers & NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Pain Relievers & NSAIDs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Pain Relievers & NSAIDs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Antidepressant & Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Antidepressant & Antipsychotic Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Antidepressant & Antipsychotic Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Antimicrobial & Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Antimicrobial & Immunomodulatory Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Antimicrobial & Immunomodulatory Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Hospitals Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Hospitals Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Specialty Clinics Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Specialty Clinics Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 23: USA Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 24: USA Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: USA 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 26: USA Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 29: Canada Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: Canada Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: Canada 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• JAPAN
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 35: Japan Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Japan Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Japan 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• CHINA
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 41: China Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: China Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: China 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 44: China Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• EUROPE
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 47: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 48: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• FRANCE
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 56: France Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: France Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: France 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 59: France Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• GERMANY
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 62: Germany Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: Germany Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: Germany 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 68: Italy Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Italy Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Italy 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 74: UK Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: UK Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: UK 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 77: UK Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• SPAIN
  • TABLE 80: Spain Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: Spain Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: Spain 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 83: Spain Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Spain Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Spain 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• RUSSIA
  • TABLE 86: Russia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Russia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Russia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 89: Russia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Russia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Russia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Rest of Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Rest of Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of Europe Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of Europe 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 99: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 102: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 103: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 105: Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 106: Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• AUSTRALIA
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
  • TABLE 107: Australia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 108: Australia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 109: Australia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 110: Australia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 111: Australia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 112: Australia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• INDIA
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
  • TABLE 113: India Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 114: India Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 115: India 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 116: India Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 117: India Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 118: India 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• SOUTH KOREA
  • TABLE 119: South Korea Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 120: South Korea Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 121: South Korea 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 122: South Korea Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 123: South Korea Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 124: South Korea 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 126: Rest of Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 129: Rest of Asia-Pacific Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• LATIN AMERICA
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
  • TABLE 131: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 132: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 133: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2024 & 2030
  • TABLE 134: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 135: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 136: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 137: Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 138: Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 139: Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• ARGENTINA
  • TABLE 140: Argentina Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 141: Argentina Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 142: Argentina 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 143: Argentina Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 144: Argentina Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 145: Argentina 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• BRAZIL
  • TABLE 146: Brazil Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 147: Brazil Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 148: Brazil 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 149: Brazil Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 150: Brazil Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 151: Brazil 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• MEXICO
  • TABLE 152: Mexico Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 153: Mexico Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 154: Mexico 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 155: Mexico Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 156: Mexico Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 157: Mexico 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• REST OF LATIN AMERICA
  • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 159: Rest of Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 160: Rest of Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 162: Rest of Latin America Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 163: Rest of Latin America 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• MIDDLE EAST
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
  • TABLE 164: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 165: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 166: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2024 & 2030
  • TABLE 167: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 168: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 169: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 170: Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 171: Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 172: Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• IRAN
  • TABLE 173: Iran Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 174: Iran Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 175: Iran 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 176: Iran Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 177: Iran Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 178: Iran 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• ISRAEL
  • TABLE 179: Israel Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 180: Israel Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 181: Israel 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 182: Israel Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 183: Israel Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 184: Israel 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• SAUDI ARABIA
  • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 186: Saudi Arabia Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 187: Saudi Arabia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 189: Saudi Arabia Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 190: Saudi Arabia 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• UNITED ARAB EMIRATES
  • TABLE 191: UAE Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 192: UAE Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 193: UAE 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 194: UAE Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 195: UAE Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 196: UAE 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• REST OF MIDDLE EAST
  • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 198: Rest of Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 199: Rest of Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 201: Rest of Middle East Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 202: Rest of Middle East 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030
• AFRICA
  • Chronic Fatigue Syndrome Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
  • TABLE 203: Africa Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 204: Africa Historic Review for Chronic Fatigue Syndrome Therapeutics by Type - Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 205: Africa 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Type - Percentage Breakdown of Value Sales for Pain Relievers & NSAIDs, Antidepressant & Antipsychotic Drugs and Antimicrobial & Immunomodulatory Drugs for the Years 2014, 2024 & 2030
  • TABLE 206: Africa Recent Past, Current & Future Analysis for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 207: Africa Historic Review for Chronic Fatigue Syndrome Therapeutics by Application - Hospitals Application, Specialty Clinics Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 208: Africa 16-Year Perspective for Chronic Fatigue Syndrome Therapeutics by Application - Percentage Breakdown of Value Sales for Hospitals Application, Specialty Clinics Application and Other Applications for the Years 2014, 2024 & 2030

IV. COMPETITION